Европейская академия естественных наук Hannover E.V.

Zhonghui Zheng

Prof. Zhonghui Zheng, male, born in August 1971, is a distinguished researcher. He holds a Ph.D. from Peking Union Medical College, and has completed a postdoctoral fellowship at Peking Union Medical College. He is recognized as “Taishan Leading Industrial Talent”. Furthermore, he has served as a Senior Visiting Scholar at the Irvine Medical Center of the University of California. Currently, he holds the position of Chief Engineer and Chief Scientist at Shandong Xinhua Pharmaceutical Co., Ltd. He is also the Chairman of Zibo Biomedical Doctoral Innovation Alliance and serves as a part-time doctoral supervisor at Shenyang Pharmaceutical University and a master's supervisor at Shandong University. Additionally, he is an esteemed member of the editorial board for Chinese Pharmaceutical Yearbook, Journal of Pharmaceutical Research, and Journal of China Pharmaceutical University. At the same time, he is recognized as an expert reviewer by the Ministry of Science and Technology as well as the Ministry of Industry and Information Technology.

Zheng has overseen the approval of 21 clinical trial applications for new drugs, including four class 1 new drugs He has obtained 23 drug production licenses and 3 new drug certificates. Meanwhile, he has undertaken 5 research projects at the provincial and ministerial level, granted over 20 national patents for inventions and 1 patent in the United States. His research findings have been published in more than 31 domestic and international journals, including 13 SCI papers.

Renowned as he is, Zheng has been honored with several prestigious awards, including the Second Prize for Scientific and Technological Progress in Shandong Province, the Third Prize for Scientific and Technological Progress in Shandong Province, the Second Prize for Technological Invention in Shandong Province, the First Prize for Scientific and Technological Achievement awarded by the China Chemical Society, and the Second Prize for Technological Progress in the Petroleum and Chemical Industry Joint Association. In recognition of his expertise and contributions, Zheng has been acclaimed as an outstanding young expert in Zibo City. He has received esteemed titles such as “Taishan Leading Industrial Talent”, "Second-Class Merit of Science and Technology Workers in Shandong Province", and “Prominent Figure of Pharmaceutical Innovation in Shandong Province” twice in 2015 and 2022.

In his role as the technical leader of the company, Zheng has spearheaded the visionary of “Grand Research and Development Strategy” focusing on the development of challenging generic drugs and innovative small molecule chemicals. Notably, he has achieved groundbreaking success in the research and development of four class 1 new drugs in different therapy areas.These include OAB-14, an innovative drug with independent intellectual property rights, LXH-2201, a cutting-edge drug for stroke treatment, LXH-1211, a medication for pulmonary arterial hypertension, and LXH-2103, a postoperative analgesic drug. Under Zheng’s guidance, his team has established a comprehensive “Critical Public Safety and Emergency Medication” system. This system revolves around six major areas, encompassing research and development in fields such as microbial drugs for black fever and epidemic pathogens, viral diseases and toxin-related medications, microcirculation system rescue drugs, emergency medications for bleeding and vascular rupture, antiviral drugs, and major anti-infective drugs. As a visionary leader and organizer of the team, Zheng has pioneered green and intelligent production processes for active pharmaceutical ingredients, setting the industry's development trajectory. His research achievements and optimized production scale have positioned his endeavors at the forefront of international standards. Notably, his team’s efforts have led to significant advancements, such as optimizing nearly 100 techniques and establishing the world's first “continuous green industrial platform” for ibuprofen production. This platform has increased annual production capacity from 2,000 tons to 8,000 tons, solidifying their global leadership in this domain. Furthermore, their integrated “Pharmaceutical Intermediate-API” industrial platform boasts an 8,000-ton/year caffeine active pharmaceutical ingredient production line, placing them at the forefront of comprehensive technological advancements worldwide in terms of both quantity and quality. Zheng’s expertise has also driven the successful design and implementation of an industrial engineering project with an annual production capacity of 15,000 tons of aspirin active pharmaceutical ingredient. This achievement has positioned them as the world's leading producer and granted them market access to developed countries in Europe and America.

 

вверх

Zhiliang Jin

Энциклопедия ЕАЕН

Zhou Kai

 ¦  Impressum  ¦  Контакт